Table 3.

Features of the study population according to the presence of cardiovascular disease (CVD).

	CVD - (n=2363)	CVD + (n=371)	p-value
Age (years)	57.8 ± 0.4	66.7 ± 0.7	<0.001
Male sex (%)	45.3 ± 1.0	58.3 ± 4.1	0.010
Race-Ethnicity (%)			0.006
Non-Hispanic white	66.2 ± 2.9	74.3 ± 3.5
Hispanic	13.9 ± 1.9	7.7 ± 1.5
Non-Hispanic black	9.9 ± 1.6	9.7 ± 1.9
Non-Hispanic Asian	5.7 ± 1.0	2.0 ± 0.6
Other	4.3 ± 0.7	6.3 ± 2.2
Cigarette smoke (%)			<0.001
Never	60.0 ± 1.8	41.5 ± 4.2
Past	28.4 ± 1.2	41.4 ± 3.3
Current	11.6 ± 1.1	17.1 ± 2.9
BMI (Kg/m2)	30.0 ± 0.3	30.1 ± 0.4	0.601
Laboratory parameters
HbA1c (%)	5.8 ± 0.0	6.2 ± 0.1	<0.001
AST (IU/L)	20.9 ± 0.2	21.4 ± 0.7	0.443
ALT (IU/L)	21.6 ± 0.3	20.5 ± 1.0	0.282
GGT (IU/L)	28.2 ± 0.7	34.1 ± 3.3	0.080
Albumin (g/dL)	4.1 ± 0.0	4.0 ± 0.0	<0.001
Platelet count (109/L)	242.7 ± 3.6	221.1 ± 4.2	<0.001
Total Cholesterol (mg/dL)	198.4 ± 2.0	176.6 ± 5.2	0.001
Triglycerides (mg/dL)	150.3 ± 3.7	164.1 ± 7.7	0.058
HDL-Cholesterol (mg/dL)	54.2 ± 0.5	51.2 ± 1.8	0.148
Comorbidities
Type 2 diabetes (%)	16.7 ± 0.9	39.3 ± 3.1	<0.001
Blood pressure category (%)			0.001
Optimal	26.8 ± 2.3	12.6 ± 3.1
Normal	14.3 ± 1.0	9.3 ± 2.2
High-normal	9.2 ± 1.3	7.1 ± 1.7
Hypertension	49.7 ± 2.3	71.0 ± 5.3
CKD (%)	8.6 ± 0.8	25.2 ± 2.9	<0.001
Statin use (%)	21.7 ± 1.7	65.9 ± 3.6	<0.001
CAP ≥ 274 dB/m	47.1 ± 1.5	59.6 ± 3.8	0.013
LSM ≥ 8 kPa	9.3 ± 0.8	12.9 ± 2.4	0.123

Data are expressed as weighted proportions [± Standard Error (SE)] for categorical variables and as weighted means ± SE for continuous variables. Linear regression and Rao-Scott chi-square test were used to compare groups.

BMI, Body Mass Index; HbA1c, Hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltranspeptidase; HDL, high density lipoprotein; CKD, chronic kidney disease.